Stockreport

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

argenx SE - American Depositary Shares  (ARGX) 
PDF March 26, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of diff [Read more]